Multiple Promising Catalysts For Vericel Corp (NASDAQ:VCEL)


From a technical perspective, last week Vericel Corp (NASDAQ:VCEL) charts were indicating multiple-bottoming pattern close to the $ 2.30 to $2.35 price range. It came correct as in the last trading session, the stock price of Vericel jumped more than 57% to close the day at $4.10. Leading into next year and into the MACI news, the stock may gain increased momentum in the coming period.

The investment at this price level extremely attractive provided the chart assessment done by the market experts. The stock was trading right close to the 50-DMA last week and it was indicative that it can move well above it in coming weeks. Holding the 89-EMA is promising and the recent green moves are supportive of further gains leading into the catalyst event.

The highlights

While long-term research objectives focus on attaching stem cell therapies for regeneration, in the near-term, few cell treatments based medications or research exists as a feasible treatment alternative in managing cartilage wounds. Lxmyelocel T comes in the list of autologous multicellular treatments intended to cure advanced heart failure followed ischemic dilated cardiomyopathy. One of these two medications, MACI is in pipeline assessment with the FDA next month.

While this article isn’t more focused on clinically investigative part, it tries to provide a perspective in the cell treatment research performed by Vericel in combination with past successes with Carticel and Epicel. When accounting such alternate treatment processes, safety concerns are especially vital, mainly for non-life-threatening problems.

The risks linked in short-term processing are mainly the risk of compromised sterile method or cell toxicity while processing. Culture expansion procedures launch the additional risk of unintended selection of clones with disagreeable genetic or epigenetic changes. Having assessed the details of Vericel demonstrations on MACI, the analysts are forced to believe that currently there aren’t any identified safety issues, particularly in the arrangement of autogenous cell transplantation.


Please enter your comment!
Please enter your name here